Global Pd 1 And Pdl1 Inhibitors Or Immune Checkpoint Inhibitors Market Size 2024, Forecast To 2033
6 Mar, 2024
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $39.8 billion in 2023 to $46.29 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth in the historic period can be attributed to immunotherapy advancements, increased clinical success and approvals, increased cancer incidence, shift in cancer treatment paradigm, collaborations and research investments. The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to expanding indications, biomarker research and personalized medicine, clinical trials and research collaborations, global healthcare infrastructure development. Major trends in the forecast period include focus on patient access and affordability, global clinical trial collaborations, immunotherapy combinations, patient-centric approaches, regulatory updates, and approvals.
Global PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Market Key Driver
The rising prevalence of cancer cases is poised to propel the growth of the PD-1 and PDL1 Inhibitors/Immune checkpoint inhibitors market in the coming years. Cancer, characterized by the uncontrolled proliferation and spread of abnormal cells, poses significant health challenges worldwide. PD-1 and PD-L1 inhibitors represent groundbreaking therapies that harness the body's immune system to combat cancer cells effectively. The escalating incidence of cancer cases underscores the critical need for innovative treatment modalities, thus driving the demand for PD-1 and PDL1 inhibitors. According to the European Union Science Hub in October 2023, the preceding two years witnessed a 2.3% increase in new cancer cases, totaling 2.74 million, along with a corresponding 2.4% rise in cancer-related mortality. Consequently, the growing prevalence of cancer underscores the pivotal role of PD-1 and PDL1 inhibitors in advancing cancer treatment modalities and driving the growth of the respective market segment.
Get A Free Sample Of The Global PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Market ReportGlobal PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Market Segments
The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market covered in this report is segmented –
1) By Product: Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab
2) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies
3) By Application: Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma, Colorectal Cancer, Other Applications
4) By End-Users : Hospitals, Specialty Clinics, Academic and Research Institutions
By Geography:The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
North America was the largest region in the PD-1 and PDL1 inhibitors market in 2023. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Industry Players
Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd, Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd, Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd, Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.
Get The Full Global PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Market Report
PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Market Overview
PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors
PD 1 and PDL1 Inhibitors or Immune Checkpoint Inhibitors Global Market Report 2023 provides data on the global pd 1 and pdl1 inhibitors or immune checkpoint inhibitors market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The pd 1 and pdl1 inhibitors or immune checkpoint inhibitors market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.